Financial Comparison: Assure (OTCMKTS:IONM) and Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX – Get Free Report) and Assure (OTCMKTS:IONM – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 3.3% of Assure shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 3.8% of Assure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Virax Biolabs Group and Assure’s net margins, return on equity and return on assets.

Volatility & Risk

Virax Biolabs Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Assure has a beta of 201.2, suggesting that its stock price is 20,020% more volatile than the S&P 500.

Earnings and Valuation

This table compares Virax Biolabs Group and Assure”s top-line revenue, earnings per share and valuation.

Virax Biolabs Group has higher earnings, but lower revenue than Assure.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Virax Biolabs Group and Assure, as reported by MarketBeat.

Virax Biolabs Group presently has a consensus price target of $25.00, indicating a potential upside of 774.13%. Given Virax Biolabs Group’s stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Assure.

Summary

Virax Biolabs Group beats Assure on 7 of the 9 factors compared between the two stocks.

About Virax Biolabs Group

(Get Free Report)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About Assure

(Get Free Report)

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.